Business Context and Reporting Period
This Form 8-K Current Report from Collegium Pharmaceutical, Inc. (NASDAQ: COLL) covers events occurring on May 20, 2021, specifically the Company's Annual Meeting of Shareholders. The filing details the results of shareholder votes and subsequent changes to the Board of Directors and executive management.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
Board of Directors Resignation
Director Theodore Schroeder received a greater number of votes against his re-election than in favor. In accordance with Corporate Governance Guidelines, he tendered his resignation, which the Board accepted effective May 21, 2021. The resignation was not the result of any dispute with the Company.
Executive Appointment
Colleen Tupper succeeded Paul Brannelly as Executive Vice President and Chief Financial Officer, effective May 24, 2021. An Employment Agreement was executed on this date, with terms previously disclosed in a May 6, 2021 filing.
Voting Results and Shareholder Matters
As of the record date (March 31, 2021), 35,203,824 shares were entitled to vote, with 32,368,721 shares present at the meeting.
- Proposal 1 (Election of Directors): Rita Balice-Gordon, Garen Bohlin, and Gwen Melincoff were re-elected. Theodore Schroeder was not re-elected (5,412,461 votes for vs. 24,648,871 votes against).
- Proposal 2 (Executive Compensation): Shareholders approved the advisory compensation of named executive officers (29,689,528 votes for vs. 353,660 votes against).
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm (32,359,485 votes for vs. 6,426 votes against).
Outlook, Risks, and Contingencies
The filing does not provide updated financial guidance or discuss new material risks. The primary contingency noted is the transition of the CFO role and the reduction of the Board size following Mr. Schroeder's resignation.
Investor Verification Checklist
- Verify the effective date of Colleen Tupper's CFO appointment (May 24, 2021) and review the full Employment Agreement terms when filed as an exhibit to the Q2 2021 Form 10-Q.
- Confirm the composition of the Board of Directors following the acceptance of Theodore Schroeder's resignation.
- Review the May 6, 2021 Form 8-K for the original disclosure of Ms. Tupper's appointment terms.